Research Article
IDH1/IDH2 but Not TP53 Mutations Predict Prognosis in Bulgarian Glioblastoma Patients
Table 2
Clinical features of the patients with mutations in IDH1/IDH2 and TP53 genes.
| Clinical characteristics | N () | IDH1/IDH2 mutated () | TP53 mutated () |
| Gender | | | | Male | 53 | 8 (15.1%) | 20 (37.7%) | Female | 53 | 6 (11.3%) | 17 (32.1%) | Age | | | | <56 years old | 51 | 12 (23.5%) | 22 (43.1%) | ≥56 years old | 55 | 2 (0.36%) | 15 (27.3%) | Karnofsky Scalea | | | | KPS ≤70 | 56 | 3 (0.5%) | 15 (26.8%) | KPS >70 | 45 | 10 (22.2%) | 21 (46.6%) | Resectiona | | | | Subtotal or partial | 54 | 10 (18.5%) | 21 (38.8%) | Total | 50 | 4 (0.8%) | 16 (32%) | Glioblastoma type | | | | Primary | 93 | 10 (10.7%) | 29 (31.2%) | Secondary | 13 | 4 (30.7%) | 8 (61.5%) | Overall survivala (months) | | | | Median | 7.7 | 30.9 | 9.1 |
|
|
Missing data for several patients. N: number of patients.
|